154 related articles for article (PubMed ID: 34556806)
1. Delayed administration of ixazomib modifies the immune response and prevents chronic graft-versus-host disease.
Ramos TL; García-Guerrero E; Caballero-Velázquez T; Rodríguez-Gil A; Caracuel-García R; Nufer M; Robles-Frías MJ; Barbado MV; Pérez-Simón JA
Bone Marrow Transplant; 2021 Dec; 56(12):3049-3058. PubMed ID: 34556806
[TBL] [Abstract][Full Text] [Related]
2. Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone.
Al-Homsi AS; Goodyke A; McLane M; Abdel-Mageed S; Cole K; Muilenburg M; Feng Y
Biol Blood Marrow Transplant; 2017 Feb; 23(2):255-261. PubMed ID: 27888016
[TBL] [Abstract][Full Text] [Related]
3. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
4. Targeting Sirt-1 controls GVHD by inhibiting T-cell allo-response and promoting Treg stability in mice.
Daenthanasanmak A; Iamsawat S; Chakraborty P; Nguyen HD; Bastian D; Liu C; Mehrotra S; Yu XZ
Blood; 2019 Jan; 133(3):266-279. PubMed ID: 30514750
[TBL] [Abstract][Full Text] [Related]
5. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
[TBL] [Abstract][Full Text] [Related]
6. Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect.
Ilan Y; Margalit M; Ohana M; Gotsman I; Rabbani E; Engelhardt D; Nagler A
Hum Immunol; 2005 Mar; 66(3):231-40. PubMed ID: 15784461
[TBL] [Abstract][Full Text] [Related]
7. [Influence of donor Treg cells on GVHD and GVL effects after allogeneic bone marrow transplantation in mice].
Cao J; Chen C; Zeng LY; Li ZY; Cheng H; Pan XY; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):181-4. PubMed ID: 20137143
[TBL] [Abstract][Full Text] [Related]
8. Preimplantation factor reduces graft-versus-host disease by regulating immune response and lowering oxidative stress (murine model).
Azar Y; Shainer R; Almogi-Hazan O; Bringer R; Compton SR; Paidas MJ; Barnea ER; Or R
Biol Blood Marrow Transplant; 2013 Apr; 19(4):519-28. PubMed ID: 23266739
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant bendamustine reduces GvHD while preserving GvL in experimental haploidentical bone marrow transplantation.
Stokes J; Hoffman EA; Zeng Y; Larmonier N; Katsanis E
Br J Haematol; 2016 Jul; 174(1):102-16. PubMed ID: 27030315
[TBL] [Abstract][Full Text] [Related]
10. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
Hattori K; Hirano T; Oshimi K; Yagita H; Okumura K
Leuk Lymphoma; 2000 Aug; 38(5-6):553-61. PubMed ID: 10953977
[TBL] [Abstract][Full Text] [Related]
11. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
12. Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.
Li JM; Petersen CT; Li JX; Panjwani R; Chandra DJ; Giver CR; Blazar BR; Waller EK
Cancer Res; 2016 Dec; 76(23):6802-6815. PubMed ID: 27671676
[TBL] [Abstract][Full Text] [Related]
13. [The effect of HGF on graft-versus-host disease and graft-versus-leukemia after allogeneic bone marrow transplantation in acute lymphoblastic leukemia mice].
Xia YJ; Gao QP; Wan CC; Cheng FJ; Liu ZX; Guo RC
Zhonghua Xue Ye Xue Za Zhi; 2005 Jul; 26(7):404-7. PubMed ID: 16251021
[TBL] [Abstract][Full Text] [Related]
14. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion.
Al-Homsi AS; Goodyke A; Cole K; Muilenburg M; McLane M; Abdel-Mageed S; Feng Y
Exp Hematol; 2017 Apr; 48():50-57. PubMed ID: 28007655
[TBL] [Abstract][Full Text] [Related]
16. [Effect of Ly49A transfected mouse spleen cells on graft versus host disease and graft versus leukemia after haploidentical allogeneic bone marrow transplantation in mice].
Li Y; Guo K; Chen Y; Song Z; Li J; Deng L
Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):411-4. PubMed ID: 12411044
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation.
Imado T; Iwasaki T; Kataoka Y; Kuroiwa T; Hara H; Fujimoto J; Sano H
Blood; 2004 Sep; 104(5):1542-9. PubMed ID: 15100150
[TBL] [Abstract][Full Text] [Related]
18. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
Sykes M; Harty MW; Szot GL; Pearson DA
Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
[TBL] [Abstract][Full Text] [Related]
20. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
